View Item 

Show simple item record

Attenuation of Murine Collagen‐Induced Arthritis by Targeting CD6
dc.contributor.authorLi, Yan
dc.contributor.authorRuth, Jeffrey H.
dc.contributor.authorRasmussen, Stephanie M.
dc.contributor.authorAthukorala, Kalana S.
dc.contributor.authorWeber, Daniel P.
dc.contributor.authorAmin, M. Asif
dc.contributor.authorCampbell, Phillip L.
dc.contributor.authorSinger, Nora G.
dc.contributor.authorFox, David A.
dc.contributor.authorLin, Feng
dc.date.accessioned2020-09-02T15:02:44Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-09-02T15:02:44Z
dc.date.issued2020-09
dc.identifier.citationLi, Yan; Ruth, Jeffrey H.; Rasmussen, Stephanie M.; Athukorala, Kalana S.; Weber, Daniel P.; Amin, M. Asif; Campbell, Phillip L.; Singer, Nora G.; Fox, David A.; Lin, Feng (2020). "Attenuation of Murine Collagen‐Induced Arthritis by Targeting CD6." Arthritis & Rheumatology 72(9): 1505-1513.
dc.identifier.issn2326-5191
dc.identifier.issn2326-5205
dc.identifier.urihttps://hdl.handle.net/2027.42/156498
dc.publisherWiley Periodicals, Inc.
dc.titleAttenuation of Murine Collagen‐Induced Arthritis by Targeting CD6
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelRheumatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/156498/2/art41288_am.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/156498/1/art41288.pdfen_US
dc.identifier.doi10.1002/art.41288
dc.identifier.sourceArthritis & Rheumatology
dc.identifier.citedreferenceRabquer BJ, Amin MA, Teegala N, Shaheen MK, Tsou P, Ruth JH, et al. Junctional adhesion molecule‐C is a soluble mediator of angiogenesis. J Immunol 2010; 185: 1777 – 85.
dc.identifier.citedreferenceSinger NG, Fox DA, Haqqi TM, Beretta L, Endres JS, Prohaska S, et al. CD6: expression during development, apoptosis and selection of human and mouse thymocytes. Int Immunol 2002; 14: 585 – 97.
dc.identifier.citedreferenceDe Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT, et al. Meta‐analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009; 41: 776 – 82.
dc.identifier.citedreferenceConsuegra‐Fernandez M, Julia M, Martinez‐Florensa M, Aranda F, Catala C, Armiger‐Borras N, et al. Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis. Cell Mol Immunol 2018; 15: 898 – 906.
dc.identifier.citedreferenceKrupashankar DS, Dogra S, Kura M, Saraswat A, Budamakuntla L, Sumathy TK, et al. Efficacy and safety of itolizumab, a novel anti‐CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double‐blind, randomized, placebo‐controlled, phase III study. J Am Acad Dermatol 2014; 71: 484 – 92.
dc.identifier.citedreferenceBowen MA, Patel DD, Li X, Modrell B, Malacko AR, Wang WC, et al. Cloning, mapping, and characterization of activated leukocyte‐cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med 1995; 181: 2213 – 20.
dc.identifier.citedreferenceEnyindah‐Asonye G, Li Y, Ruth JH, Spassov DS, Hebron KE, Zijlstra A, et al. CD318 is a ligand for CD6. Proc Natl Acad Sci U S A 2017; 114: E6912 – 21.
dc.identifier.citedreferenceLecuyer MA, Saint‐Laurent O, Bourbonniere L, Larouche S, Larochelle C, Michel L, et al. Dual role of ALCAM in neuroinflammation and blood‐brain barrier homeostasis. Proc Natl Acad Sci U S A 2017; 114: E524 – 33.
dc.identifier.citedreferenceLevesque MC, Heinly CS, Whichard LP, Patel DD. Cytokine‐regulated expression of activated leukocyte cell adhesion molecule (CD166) on monocyte‐lineage cells and in rheumatoid arthritis synovium. Arthritis Rheum 1998; 41: 2221 – 9.
dc.identifier.citedreferenceJoo YS, Singer NG, Endres JL, Sarkar S, Kinne RW, Marks RM, et al. Evidence for the expression of a second CD6 ligand by synovial fibroblasts. Arthritis Rheum 2000; 43: 329 – 35.
dc.identifier.citedreferenceSaifullah MK, Fox DA, Sarkar S, Abidi SM, Endres J, Piktel J, et al. Expression and characterization of a novel CD6 ligand in cells derived from joint and epithelial tissues. J Immunol 2004; 173: 6125 – 33.
dc.identifier.citedreferenceSinger NG, Mitra R, Lialios F, Richardson BC, Marks RM, Pesando JM, et al. CD6 dependent interactions of T cells and keratinocytes: functional evidence for a second CD6 ligand on γ‐interferon activated keratinocytes. Immunol Lett 1997; 58: 9 – 14.
dc.identifier.citedreferenceBrand DD, Latham KA, Rosloniec EF. Collagen‐induced arthritis. Nat Protoc 2007; 2: 1269 – 75.
dc.identifier.citedreferenceRuth JH, Amin MA, Woods JM, He X, Samuel S, Yi N, et al. Accelerated development of arthritis in mice lacking endothelial selectins. Arthritis Res Ther 2005; 7: R959 – 70.
dc.identifier.citedreferenceBott CM, Doshi JB, Morimoto C, Romain PL, Fox DA. Activation of human T cells through CD6: functional effects of a novel anti‐CD6 monoclonal antibody and definition of four epitopes of the CD6 glycoprotein. Int Immunol 1993; 5: 783 – 92.
dc.identifier.citedreferenceChowdhury K, Kumar U, Das S, Chaudhuri J, Kumar P, Kanjilal M, et al. Synovial IL‐9 facilitates neutrophil survival, function and differentiation of Th17 cells in rheumatoid arthritis. Arthritis Res Ther 2018; 20: 18.
dc.identifier.citedreferenceGangemi RM, Swack JA, Gaviria DM, Romain PL. Anti‐T12, an anti‐CD6 monoclonal antibody, can activate human T lymphocytes. J Immunol 1989; 143: 2439 – 47.
dc.identifier.citedreferenceIsozaki T, Arbab AS, Haas CS, Amin MA, Arendt MD, Koch AE, et al. Evidence that CXCL16 is a potent mediator of angiogenesis and is involved in endothelial progenitor cell chemotaxis: studies in mice with K/BxN serum–induced arthritis. Arthritis Rheum 2013; 65: 1736 – 46.
dc.identifier.citedreferenceIsozaki T, Amin MA, Arbab AS, Koch AE, Ha CM, Edhayan G, et al. Inhibitor of DNA binding 1 as a secreted angiogenic transcription factor in rheumatoid arthritis. Arthritis Res Ther 2014; 16: R68.
dc.identifier.citedreferenceZhang L, Li Y, Qiu W, Bell BA, Dvorina N, Baldwin WM III, et al. Targeting CD6 for the treatment of experimental autoimmune uveitis. J Autoimmun 2018; 90: 84 – 93.
dc.identifier.citedreferenceIbanez A, Sarrias MR, Farnos M, Gimferrer I, Serra‐Pages C, Vives J, et al. Mitogen‐activated protein kinase pathway activation by the CD6 lymphocyte surface receptor. J Immunol 2006; 177: 1152 – 9.
dc.identifier.citedreferenceKobarg J, Whitney GS, Palmer D, Aruffo A, Bowen MA. Analysis of the tyrosine phosphorylation and calcium fluxing of human CD6 isoforms with different cytoplasmatic domains. Eur J Immunol 1997; 27: 2971 – 80.
dc.identifier.citedreferenceHafler DA, Fallis RJ, Dawson DM, Schlossman SF, Reinherz EL, Weiner HL. Immunologic responses of progressive multiple sclerosis patients treated with an anti‐T‐cell monoclonal antibody, anti‐T12. Neurology 1986; 36: 777 – 84.
dc.identifier.citedreferenceCarpenter CB, Milford EL, Reinherz EL, Schlossman SF, Tilney NL, Strom TB, et al. Monoclonal anti‐T12 antibody as therapy for renal allograft rejection. Trans Assoc Am Physicians 1983; 96: 84 – 92.
dc.identifier.citedreferenceConsuegra‐Fernandez M, Lin F, Fox DA, Lozano F. Clinical and experimental evidence for targeting CD6 in immune‐based disorders [review]. Autoimmun Rev 2018; 17: 493 – 503.
dc.identifier.citedreferenceOsorio LM, Ordonez C, Garcia CA, Jondal M, Chow SC. Evidence for protein tyrosine kinase involvement in CD6‐induced T cell proliferation. Cell Immunol 1995; 166: 44 – 52.
dc.identifier.citedreferenceBreuning J, Brown MH. T cell costimulation by CD6 is dependent on bivalent binding of a GADS/SLP-76 complex. Mol Cell Biol 2017; 37: e00071–17.
dc.identifier.citedreferenceHem CD, Ekornhol M, Granum S, Sundvold‐Gjerstad V, Spurkland A. CD6 and linker of activated T cells are potential interaction partners for T cell‐specific adaptor protein. Scand J Immunol 2017; 85: 104 – 12.
dc.identifier.citedreferenceRoncagalli R, Hauri S, Fiore F, Liang Y, Chen Z, Sansoni A, et al. Quantitative proteomics analysis of signalosome dynamics in primary T cells identifies the surface receptor CD6 as a Lat adaptor‐independent TCR signaling hub. Nat Immunol 2014; 15: 384 – 92.
dc.identifier.citedreferenceOrta‐Mascaro M, Consuegra‐Fernandez M, Carreras E, Roncagalli R, Carreras‐Sureda A, Alvarez P, et al. CD6 modulates thymocyte selection and peripheral T cell homeostasis. J Exp Med 2016; 213: 1387 – 97.
dc.identifier.citedreferenceLi Y, Singer NG, Whitbred J, Bowen MA, Fox DA, Lin F. CD6 as a potential target for treating multiple sclerosis. Proc Natl Acad Sci U S A 2017; 114: 2687 – 92.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
art41288.pdf
Size:
882.6KB
Format:
PDF
View/Open
Name:
art41288_am.pdf
Size:
373.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.